Cargando…
Contribution of Epithelial-Mesenchymal Transition to Pancreatic Cancer Progression
Pancreatic adenocarcinoma (PDAC) is one of the most lethal human malignancies, with median survival of less than one year and overall five-year survival of less than 5%. There is increasing evidence demonstrating that epithelial-mesenchymal transition (EMT) contributes to pancreatic cancer metastasi...
Autores principales: | Krantz, Seth B., Shields, Mario A., Dangi-Garimella, Surabhi, Bentrem, David J., Munshi, Hidayatullah G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840442/ https://www.ncbi.nlm.nih.gov/pubmed/24281219 http://dx.doi.org/10.3390/cancers2042084 |
Ejemplares similares
-
Three-Dimensional Collagen I Promotes Gemcitabine Resistance In Vitro in Pancreatic Cancer Cells through HMGA2-Dependent Histone Acetyltransferase Expression
por: Dangi-Garimella, Surabhi, et al.
Publicado: (2013) -
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
por: Pham, Thao N. D., et al.
Publicado: (2021) -
SET contributes to the epithelial-mesenchymal transition of pancreatic cancer
por: Mody, Hardik R., et al.
Publicado: (2017) -
Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer
por: Kumar, Krishan, et al.
Publicado: (2023) -
Quercetin Enhances the Anti-Tumor Effects of BET Inhibitors by Suppressing hnRNPA1
por: Pham, Thao N.D., et al.
Publicado: (2019)